CAMP4 Therapeutics (NASDAQ:CAMP) Issues Quarterly Earnings Results

CAMP4 Therapeutics (NASDAQ:CAMP) posted its quarterly earnings data on Thursday. The Wireless communications provider reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.17), FiscalAI reports. The firm had revenue of $1.90 million for the quarter. CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%.

CAMP4 Therapeutics Stock Up 9.1%

CAMP stock traded up $0.34 during trading hours on Friday, hitting $4.06. The company’s stock had a trading volume of 128,677 shares, compared to its average volume of 189,985. The company has a market capitalization of $254.76 million, a PE ratio of -1.90 and a beta of 0.28. CAMP4 Therapeutics has a 12 month low of $2.90 and a 12 month high of $7.75. The stock has a 50 day moving average price of $3.84 and a two-hundred day moving average price of $4.20.

Insider Buying and Selling at CAMP4 Therapeutics

In other news, Director Andrew Schwab sold 400,000 shares of the firm’s stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $4.04, for a total transaction of $1,616,000.00. Following the transaction, the director owned 2,033,270 shares in the company, valued at approximately $8,214,410.80. This trade represents a 16.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Kelly Gold acquired 10,000 shares of CAMP4 Therapeutics stock in a transaction that occurred on Monday, August 31st. The stock was acquired at an average cost of $3.96 per share, with a total value of $39,600.00. Following the purchase, the chief financial officer owned 10,000 shares in the company, valued at $39,600. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have sold 593,613 shares of company stock worth $2,504,037. 21.69% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On CAMP4 Therapeutics

Institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE bought a new stake in shares of CAMP4 Therapeutics during the 2nd quarter worth about $78,000. Trails Edge Capital Partners LP acquired a new position in shares of CAMP4 Therapeutics during the 2nd quarter valued at about $8,446,935. Jupiter Topco LLC bought a new position in shares of CAMP4 Therapeutics in the 2nd quarter valued at approximately $27,581,000. 5AM Venture Management LLC acquired a new position in CAMP4 Therapeutics during the 2nd quarter worth $25,647,928. Finally, BlackRock Inc. acquired a new position in shares of CAMP4 Therapeutics during the 2nd quarter worth about $7,185,000.

Analyst Upgrades and Downgrades

Several research firms recently commented on CAMP. Chardan Capital decreased their price target on shares of CAMP4 Therapeutics from $6.50 to $6.00 and set a “buy” rating for the company in a report on Tuesday, September 29th. UBS Group set a $15.00 price objective on shares of CAMP4 Therapeutics in a research note on Friday, August 14th. Zacks Research upgraded shares of CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, August 17th. Wall Street Zen upgraded shares of CAMP4 Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of CAMP4 Therapeutics in a research note on Tuesday, September 29th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $10.44.

CAMP4 Therapeutics Company Profile

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing medicines that increase the production of disease-relevant proteins by activating the expression of specific genes. The company’s approach is designed to address diseases caused by insufficient protein levels, including certain genetic disorders in which boosting activity from a functional gene copy may provide therapeutic benefit.

CAMP4 uses its Regulatory Action Platform, or RAP, to identify regulatory elements that control RNA production and discover small-molecule compounds capable of increasing the expression of selected genes.